These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

559 related articles for article (PubMed ID: 33032842)

  • 1. Comparative Efficacy of Acalabrutinib in Frontline Treatment of Chronic Lymphocytic Leukemia: A Systematic Review and Network Meta-analysis.
    Davids MS; Waweru C; Le Nouveau P; Padhiar A; Singh G; Abhyankar S; Leblond V
    Clin Ther; 2020 Oct; 42(10):1955-1974.e15. PubMed ID: 33032842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Efficacy of First-Line Treatments of Chronic Lymphocytic Leukemia: Network Meta-Analyses of Survival Curves.
    Alrawashdh N; Persky DO; McBride A; Sweasy J; Erstad B; Abraham I
    Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):e820-e831. PubMed ID: 34274291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial.
    Sharman JP; Egyed M; Jurczak W; Skarbnik A; Pagel JM; Flinn IW; Kamdar M; Munir T; Walewska R; Corbett G; Fogliatto LM; Herishanu Y; Banerji V; Coutre S; Follows G; Walker P; Karlsson K; Ghia P; Janssens A; Cymbalista F; Woyach JA; Salles G; Wierda WG; Izumi R; Munugalavadla V; Patel P; Wang MH; Wong S; Byrd JC
    Lancet; 2020 Apr; 395(10232):1278-1291. PubMed ID: 32305093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison Between Venetoclax-based and Bruton Tyrosine Kinase Inhibitor-based Therapy as Upfront Treatment of Chronic Lymphocytic Leukemia (CLL): A Systematic Review and Network Meta-analysis.
    Molica S; Giannarelli D; Montserrat E
    Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):216-223. PubMed ID: 33199185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of acalabrutinib plus obinutuzumab, ibrutinib plus obinutuzumab and venetoclax plus obinutuzumab for untreated CLL: a network meta-analysis.
    Sheng Z; Song S; Yu M; Zhu H; Gao A; Gao W; Ran X; Huo D
    Leuk Lymphoma; 2020 Dec; 61(14):3432-3439. PubMed ID: 32862749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Systematic Review and Network Meta-Analysis to Evaluate the Comparative Efficacy of Interventions for Unfit Patients with Chronic Lymphocytic Leukemia.
    Städler N; Shang A; Bosch F; Briggs A; Goede V; Berthier A; Renaudin C; Leblond V
    Adv Ther; 2016 Oct; 33(10):1814-1830. PubMed ID: 27535291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative Efficacy of Ibrutinib Versus Obinutuzumab + Chlorambucil in First-Line Treatment of Chronic Lymphocytic Leukemia: A Matching-Adjusted Indirect Comparison.
    Van Sanden S; Baculea S; Diels J; Cote S
    Adv Ther; 2017 Jul; 34(7):1650-1661. PubMed ID: 28573505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study.
    Davids MS; Lampson BL; Tyekucheva S; Wang Z; Lowney JC; Pazienza S; Montegaard J; Patterson V; Weinstock M; Crombie JL; Ng SY; Kim AI; Jacobson CA; LaCasce AS; Armand P; Arnason JE; Fisher DC; Brown JR
    Lancet Oncol; 2021 Oct; 22(10):1391-1402. PubMed ID: 34534514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A network meta-analysis of progression free survival and overall survival in first-line treatment of chronic lymphocytic leukemia.
    Ladyzynski P; Molik M; Foltynski P
    Cancer Treat Rev; 2015 Feb; 41(2):77-93. PubMed ID: 25512118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An indirect comparison of acalabrutinib with and without obinutuzumab vs zanubrutinib in treatment-naive CLL.
    Kittai AS; Allan JN; James D; Bridge H; Miranda M; Yong ASM; Fam F; Roos J; Shetty V; Skarbnik A; Davids MS
    Blood Adv; 2024 Jun; 8(11):2861-2869. PubMed ID: 38598745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EMA Review of Acalabrutinib for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia.
    Delgado J; Josephson F; Camarero J; Garcia-Ochoa B; Lopez-Anglada L; Prieto-Fernandez C; van Hennik PB; Papadouli I; Gisselbrecht C; Enzmann H; Pignatti F
    Oncologist; 2021 Mar; 26(3):242-249. PubMed ID: 33486852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular-Biology-Driven Frontline Treatment for Chronic Lymphocytic Leukemia: A Network Meta-Analysis of Randomized Clinical Trials.
    Rizzuto A; Pirrera A; Gigliotta E; Mancuso S; Vullo C; Camarda GM; Rotolo C; Roppolo A; Spoto C; Gentile M; Botta C; Siragusa S
    Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Matching-adjusted indirect comparisons of safety and efficacy of acalabrutinib versus other targeted therapies in patients with treatment-naïve chronic lymphocytic leukemia.
    Davids MS; Telford C; Abhyankar S; Waweru C; Ringshausen I
    Leuk Lymphoma; 2021 Oct; 62(10):2342-2351. PubMed ID: 33955326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of a 12-month fixed-duration venetoclax treatment in combination with obinutuzumab in first-line, unfit chronic lymphocytic leukemia in the United States.
    Chatterjee A; Shapouri S; Manzoor BS; Ravelo A; Sail K; Qendri V; van de Wetering G; Davids MS
    J Manag Care Spec Pharm; 2021 Nov; 27(11):1532-1544. PubMed ID: 34714110
    [No Abstract]   [Full Text] [Related]  

  • 15. Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group.
    Herishanu Y; Shaulov A; Fineman R; Bašić-Kinda S; Aviv A; Wasik-Szczepanek E; Jaksic O; Zdrenghea M; Greenbaum U; Mandac I; Simkovic M; Morawska M; Benjamini O; Spacek M; Nemets A; Bairey O; Trentin L; Ruchlemer R; Laurenti L; Stanca Ciocan O; Doubek M; Shvidel L; Dali N; Mirás F; De Meûter A; Dimou M; Mauro FR; Coscia M; Bumbea H; Szász R; Tadmor T; Gutwein O; Gentile M; Scarfò L; Tedeschi A; Sportoletti P; Gimeno Vázquez E; Marquet J; Assouline S; Papaioannou M; Braester A; Levato L; Gregor M; Rigolin GM; Loscertales J; Medina Perez A; Nijziel MR; Popov VM; Collado R; Slavutsky I; Itchaki G; Ringelstein S; Goldschmidt N; Perry C; Levi S; Polliack A; Ghia P
    Am J Hematol; 2020 Jun; 95(6):604-611. PubMed ID: 32096887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.
    Ghia P; Pluta A; Wach M; Lysak D; Kozak T; Simkovic M; Kaplan P; Kraychok I; Illes A; de la Serna J; Dolan S; Campbell P; Musuraca G; Jacob A; Avery E; Lee JH; Liang W; Patel P; Quah C; Jurczak W
    J Clin Oncol; 2020 Sep; 38(25):2849-2861. PubMed ID: 32459600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Indirect Treatment Comparisons of Ibrutinib Versus Physician's Choice and Idelalisib Plus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia.
    Sorensen S; Wildgust M; Sengupta N; Trambitas C; Diels J; van Sanden S; Xu Y; Dorman E
    Clin Ther; 2017 Jan; 39(1):178-189.e5. PubMed ID: 28062113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MAJIC: a phase III trial of acalabrutinib + venetoclax versus venetoclax + obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.
    Ryan CE; Davids MS; Hermann R; Shahkarami M; Biondo J; Abhyankar S; Alhasani H; Sharman JP; Mato AR; Roeker LE
    Future Oncol; 2022 Oct; 18(33):3689-3699. PubMed ID: 36102212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities.
    Kater AP; Owen C; Moreno C; Follows G; Munir T; Levin MD; Benjamini O; Janssens A; Osterborg A; Robak T; Simkovic M; Stevens D; Voloshin S; Vorobyev V; Ysebaert L; Qin R; Steele AJ; Schuier N; Baeten K; Caces DB; Niemann CU
    NEJM Evid; 2022 Jul; 1(7):EVIDoa2200006. PubMed ID: 38319255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acalabrutinib-based regimens in frontline or relapsed/refractory higher-risk CLL: pooled analysis of 5 clinical trials.
    Davids MS; Sharman JP; Ghia P; Woyach JA; Eyre TA; Jurczak W; Siddiqi T; Miranda P; Shahkarami M; Butturini A; Emeribe U; Byrd JC
    Blood Adv; 2024 Jul; 8(13):3345-3359. PubMed ID: 38640349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.